NCT03924427

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects With Moderate-to-Severe Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	BMS-986165	Oral tablet administration

Timeline

• Start date: 2019-04-10
• Primary completion: 2021-03-24
• Completion: 2021-03-24
• First posted: 2019-04-23
• Last updated: 2022-11-02
• Results posted: 2022-11-02

Locations

27 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study